Georgetown University’s Lombardi Comprehensive Cancer Center researchers have identified a new way to reprogram T cells, which are infection and tumor-fighting white blood cells, so that they have a superior memory, thereby making them more effective in killing cancer cells.
Consciousness is famously a “hard problem” of science: We don’t precisely know how the physical matter in our brains translates into thoughts, sensations, and feelings. But an emerging research tool called transcranial focused ultrasound may enable researchers to learn more about the phenomenon.
A team of scientists from China has successfully created a miniature womb on a chip that mimics the complex environment of the human uterus. The research offers a new way to study the exact moment an embryo attaches to a mother’s body.
Multiple sclerosis (MS) is a chronic neurological disease characterized by nerve damage and consequent impairments in vision, movement, balance and mental function. In MS, the immune system mistakenly starts attacking myelin, the protective sheath that surrounds axons (i.e., nerve fibers) in the brain, spinal cord and optic nerves.
A “unique” AI-powered headset that can predict epileptic seizures minutes before they occur has been developed by scientists in Scotland.
Researchers from Radboud University Medical Center and University of Basel have discovered new genetic causes of inherited blindness.
MIT engineers designed capsules with biodegradable radio frequency antennas that can reveal when the pill has been swallowed.
Study is a landmark effort to understand how DNA’s physical structure influences human biology
ESPOO, Finland, Jan. 8, 2026 /PRNewswire/ — HUS Helsinki University Hospital and VTT are starting a field test of wearable sensors to develop home dialysis. A total of 36 volunteer patients will use the sensors that enable monitoring of treatment effectivity. Making home dialysis safer and better would improve life quality and save society millions of euros annually.
MINNEAPOLIS, Jan. 8, 2026 /PRNewswire/ — Saluda Medical, Inc. (ASX:SLD, “Saluda” or the “Company”), a commercial-stage medical device company focused on developing treatments for chronic neurological conditions using its novel closed-loop neuromodulation platform, announced that, as expected, its next-generation EVA™ Sensing Technology has now received CE certification for commercialization in Europe with recognition of this approval in Australia. This follows FDA approval of EVA in December 2024.